Amgen's experimental jab causes 20 per cent weight loss in early results

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in those with diabetes after a year in a phase 2 trial. Despite higher discontinuation rates compared to other drugs, MariTide's monthly dosing could offer an advantage over weekly injections. Investors were slightly disappointed with the results.